Velocity is proud to announce the MASH Council to Accelerate Research Excellence (CARE). Led by Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, the MASH CARE Council will help drive world-class operational, recruitment, and trial conduct oversight for the 20+ Velocity sites conducting liver disease research — including both metabolic dysfunction-associated steatohepatitis (MASH) and metabolic associated steatotic liver disease (MASLD) trials.
Learn more about Velocity’s MASH capabilities at https://velocityclinical.com/mash-care-council.
